Last reviewed · How we verify
Dehydration
Dehydration is a Biologic drug developed by Sodertalje Hospital. It is currently in Phase 1 development. Also known as: Furosemide för intravenous administration, Acetated Ringer´s solution, Dehydration from Furosemide.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Dehydration |
|---|---|
| Also known as | Furosemide för intravenous administration, Acetated Ringer´s solution, Dehydration from Furosemide |
| Sponsor | Sodertalje Hospital |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers (NA)
- Comparison of Two Minimally Invasive Approaches for Masking Molar-Incisor Hypomineralization Opacities (NA)
- Methods of Assessing Sweat-Electrolyte Testing (MAST) (NA)
- Evaluation of the Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft vs Standard of Care in the Treatment of Partial Thickness Thermal Burns (PHASE4)
- ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure (NA)
- Prognostic Analysis of Different Treatment Options for Cerebral Hemorrhage
- Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults (PHASE2)
- Effect of Dehydration on Sleep Quality, Cognitive Skills, and Electromyographic Responses in Combat Athletes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dehydration CI brief — competitive landscape report
- Dehydration updates RSS · CI watch RSS
- Sodertalje Hospital portfolio CI
Frequently asked questions about Dehydration
What is Dehydration?
Who makes Dehydration?
Is Dehydration also known as anything else?
What development phase is Dehydration in?
Related
- Manufacturer: Sodertalje Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Furosemide för intravenous administration, Acetated Ringer´s solution, Dehydration from Furosemide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing